Aurinia Closes At-The-Market Facility

VICTORIA, British Columbia--(BUSINESS WIRE)--
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the “Company”)
today announced that, further to its Open Market Sale Agreement with
Jefferies LLC previously disclosed on November 30, 2018, in relation to
at-the-market (“ATM”) offerings of common shares in the capital of the
Company, the Company has completed the sale of 4,608,409 common shares
at a weighted average price of US$6.55 for aggregate gross proceeds of
approximately US$30 million. No further sales will be conducted pursuant
to the ATM.

About Aurinia

Aurinia Pharmaceuticals Inc. is a clinical late-stage
biopharmaceutical company focused on developing and commercializing
therapies to treat targeted patient populations impacted by serious
diseases with a high unmet medical need. The company is currently
developing voclosporin, an investigational drug, for the potential
treatment of lupus nephritis (LN), focal segmental glomerulosclerosis
(FSGS), and dry eye syndrome (DES). The company is headquartered in
Victoria, British Columbia and focuses its development efforts globally.
For further information, see our website at www.auriniapharma.com.